Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

Reshaping Dosage Forms

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Development of Taste-Masked Oral Dispersible Tablets of Cefpodoxime Proxetil

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

Frontrunners in Bispecific Antibodies

Topic

Stephanie Sutton was an assistant editor at Pharmaceutical Technology Europe.

Articles

Figures published by the European Medicines Agency (EMA) relating to centralized procedure activities for human medicines show a significant increase in the number of positive opinions made between 2007 and 2009; however, the majority of approvals are for generic products.

EMA figures demonstrate generic dominance

EMA statistics highlighting centralized-procedure activities for human medicines show a significant increase in positive opinions made between 2007 and 2009.

EMA Statistics Reveal Generic Dominance

Capsules that can release their contents at a selected temperature have been developed by researchers in France, and could lead to the development of therapeutic agents that are applied to the skin and triggered locally by rubbing.

Capsules enable on demand drug release

Hoping to prevent the deaths of eight million children over the next decade, Bill and Melinda Gates recently committed $10 billion for child-immunization programs in the world's poorest countries.

Gates Foundation Pledges $10 Billion for Vaccines

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

Vaccine R&D is surging, but continues to raise manufacturing and regulatory challenges.

Manufacturers Look to Vaccines for Growth and Innovation

The vaccine sector is challenging for both R&D and manufacturing because a wide variety of technologies and techniques are required &#151; even the largest companies find it difficult to cover all the relevant areas of expertise &#151; and this drives up development costs and often forces companies into multiple collaborations to obtain the required expertise and technologies.

Disposables help overcome some challenges of vaccine manufacture

The Director General of the European Generic medicines Association (EGA) has reiterated the association?s Vision 2015 plan, which aims to create a globally competitive generic industry, increase patient access to affordable quality medicines and ensure sustainable healthcare in Europe.

Plan outlined for European generics

The Director-General of the European Generic medicines Association has reiterated the group's Vision 2015 plan.

New Plan for Generic Drugs in Europe

The authors sought to improve the productivity of protein synthesis by using a highly active cell-free extract from Escherichia coli and by optimizing buffer conditions and shaking conditions.

Large-Scale Protein Production with a Cell-Free System

Influenza vaccines can be produced faster using a new insect cell-based technology compared with traditional egg-based processes, according to scientists in Vienna (Austria).